Close Menu

NEW YORK (360Dx) – With a recent €50,000 ($62,000) Phase I grant from the EU's Horizon 2020 SME Instrumentation program, Swedish microfluidics firm Gradientech plans to explore the potential US market for its QuickMIC antibiotic susceptibility testing system.

Further, said CEO and Cofounder Sara Thorslund, the Phase I award makes the company eligible to receive a Phase II SME Instrumentation award, which totals between €500,000 and €2.5 million.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.